


Pharmaceuticals & Biotechnology | Large Cap
Divis Laboratories exhibits strong financial health, particularly in solvency, growth, and profitability. The company maintains a debt-free status, showcasing financial stability and low risk. Revenue, operating profit, and EPS have shown significant growth, indicating effective management and market positioning. Profitability margins such as ROCE, ROE and ROA are favorable. However, efficiency ratios are relatively low, suggesting potential challenges in asset utilization and inventory management. The company's liquidity position is strong, with high current, quick, and cash ratios, ensuring it can meet its short-term obligations. Overall, Divis Laboratories demonstrates robust financial performance, with opportunities to improve its operational efficiency.
Divis Laboratories exhibits strong financial health, particularly in solvency, growth, and profitability. The company maintains a debt-free status, showcasing financial stability and low risk. Revenue, operating profit, and EPS have shown significant growth, indicating effective management and market positioning. Profitability margins such as ROCE, ROE and ROA are favorable. However, efficiency ratios are relatively low, suggesting potential challenges in asset utilization and inventory management. The company's liquidity position is strong, with high current, quick, and cash ratios, ensuring it can meet its short-term obligations. Overall, Divis Laboratories demonstrates robust financial performance, with opportunities to improve its operational efficiency.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
84.27
Industry Median
31.04
Large Cap Median
33.25
P/E RATIO
85.55
P/B RATIO
13.11
Industry Median
3.41
Large Cap Median
5.20
P/S RATIO
20.38
Industry Median
3.35
Large Cap Median
5.66
Others
PEG RATIO
16.14
EV/EBITDA RATIO
54.68
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹8275 as on Aug 7, 2026.
The company demonstrates excellent growth across all key metrics. Strong revenue growth indicates increasing market demand and effective sales strategies. High operating profit growth reflects efficient cost management. Robust EPS and net income growth confirm enhanced profitability. Significant asset growth suggests strategic investments and expansion. These consistent high-growth rates position the company favorably for future success.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 28.57 | -13.3 | 0.99 | 19.31 | 12.82 |
| Operating Profit Growth Rate | 35.51 | -39 | -6.75 | 34.52 | 15.74 |
| Earnings Per Share (EPS) Growth | 49.19 | -38.41 | -12.26 | 36.93 | 17.21 |
| Asset Growth Rate | 24.04 | 7.97 | 7.18 | 9.45 | 18.39 |
| Net Income Growth Rate | 49.19 | -38.41 | -12.23 | 36.94 | 17.21 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Divis Laboratories Ltd | 7.91 | 85.55 | Highly Overvalued | 3441.00 | 98.20 | 2568.00 |
| 2 | Lupin Ltd | 7.84 | 20.26 | Neutral | 8816.00 | 139.24 | 5355.00 |
| 3 | Cipla Ltd | 7.62 | 30.48 | Neutral | 5883.00 | 43.51 | 3862.00 |
| 4 | Mankind Pharma Ltd | 7.61 | 53.00 | Overvalued | 3617.00 | 49.34 | 1938.00 |
| 5 | Zydus Lifesciences Ltd | 7.60 | 22.24 | Neutral | 8475.00 | 35.69 | 5124.00 |
| 6 | Dr Reddys Laboratories Ltd | 6.68 | 23.31 | Neutral | 6454.00 | 38.57 | 4158.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral